LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR UROGEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Faru ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

公司诉讼案件 - UroGen Pharma Ltd因涉嫌违反1934年证券交易法被集体诉讼 指控涉及2023年7月27日至2025年5月15日期间购买或收购其证券的投资者 [1] - 诉讼指控公司及其高管在Class Period内作出虚假或误导性陈述 或未披露关键信息 [3] - 主要指控包括ENVISION临床研究设计缺陷 未能证明UGN-102有效性 且忽视FDA关于研究设计的警告 [3] 产品与研发 - UroGen专注于开发治疗特殊癌症的解决方案 主导产品UGN-102(丝裂霉素)为治疗低级别中危非肌层浸润性膀胱癌的膀胱内溶液 [2] - FDA在2025年5月16日简报文件中指出ENVISION研究缺乏并行对照组 导致主要终点(完全缓解率和缓解持续时间)难以解释 [4] - 2025年5月21日肿瘤药物咨询委员会投票反对UGN-102新药申请 认为其风险收益比不利 [5] 市场反应 - FDA简报文件公布后 UroGen股价单日下跌近26% [4] - 新药申请被委员会否决后 股价进一步下跌45% [5] 法律程序 - 根据1995年私人证券诉讼改革法 投资者可在2025年7月28日前申请成为首席原告 [1][6] - 首席原告需为拟议集体中财务利益最大且具代表性的成员 将主导诉讼进程并选择律师事务所 [6] 律师事务所背景 - Robbins Geller律所在证券欺诈诉讼领域领先 过去五年中有四年在ISS证券集体诉讼服务排名中位列第一 [7] - 2024年为投资者追回超过25亿美元赔偿 金额超过其他五家律所总和 [7] - 曾创下72亿美元的历史最大证券集体诉讼赔偿纪录(安然公司案) [7]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ:URGN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). Investors have until J ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether UroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 16, 202 ...

LOS ANGELES, June 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 27, 2023 and May 15, 2025, inclusive (the "Class Period"), are enc ...

SAN DIEGO, June 2, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period"), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.  Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen's top current and former executives ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP宣布对UroGen Pharma Ltd及其部分高管提起集体诉讼 指控其涉嫌违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)和20(a)条款 案件由美国新泽西地区法院受理 案件编号3:25-cv-06088 [2] 涉诉原因 - 公司核心产品UGN-102(丝裂霉素)用于治疗低级别中危非肌层浸润性膀胱癌 关键三期临床试验ENVISION被指控存在信息披露问题 [3] - 公司声称ENVISION试验达到主要终点且与FDA达成协议 但FDA实际对该试验缺乏并行对照组的设计表达重大关切 [4] 股价影响 - 2025年5月16日FDA发布简报文件 质疑UGN-102有效性数据 导致股价单日下跌2.54美元(26%) 从9.85美元跌至7.31美元 [5] - 2025年5月21日肿瘤药物咨询委员会投票反对UGN-102上市申请 股价单日再跌3.37美元(45%) 从7.54美元跌至4.17美元 [6] 公司产品信息 - UroGen专注于专科癌症治疗领域 核心管线UGN-102为膀胱内灌注溶液 适应症为复发性低级别中危非肌层浸润性膀胱癌 [3] - ENVISION试验设计缺陷包括缺乏并行对照组 导致主要终点数据难以解读 且未采用FDA认可的实验设计方案 [5]